Clinical Trials
5
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)β’ Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 1
1 (25.0%)Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
Phase 2
Not yet recruiting
- Conditions
- Corona Virus InfectionCovid19
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT05017298
Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
- Conditions
- Alzheimer Disease
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Celltex Therapeutics Corporation
- Registration Number
- NCT04855955
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
Phase 2
Not yet recruiting
- Conditions
- Osteoarthritis, HipOsteoarthritis ShoulderOsteoarthritis, Knee
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT04448106
- Locations
- πΊπΈ
Stanley C Jones, Houston, Texas, United States
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
Phase 2
Not yet recruiting
- Conditions
- COVID-19
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT04428801
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
Phase 1
Not yet recruiting
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04170426
News
No news found